A Kinetic Model of the Circulatory Regulation of Tissue Plasminogen Activator

Summary

A computer simulation was developed to study the regulation of active tissue plasminogen activator (t-PA) levels in plasma by kinetically modeling t-PA secretion, t-PA inhibition by plasminogen activator inhibitor type 1 (PAI-1), and hepatic clearance of t-PA, PAI-1 and t-PA/PAI-1 complex throughout a simplified human circulatory system. The model indicates that as the active PAI-1 concentration increases, the percent of t-PA in the active form decreases exponentially. Further, the reaction between t-PA and PAI-1 substantially reduces the half-lives of both active factors. By adjusting the t-PA and PAI-1 secretion rates to provide the best fit between simulated and measured circadian variations in t-PA, PAI-1 and complex, the model predicts that the diurnal rhythm in active t-PA levels is principally due to changes in the rate of PAI-1 secretion and not to variations in the t-PA secretion rate. In conclusion, the model predicts that PAI-1 is an important regulator of the concentration, half-life and circadian variation of active t-PA.

• References

• 1 Baughman RA. Pharmacokinetics of tissue plasminogen activator. In: Tissue Plasminogen Activator in Thrombolytic Therapy.. Sobel BE, Collen D, Grossbard EB. (eds) Marcel Dekker, New York: 1987. p 41
• 2 Brommer EJP, Derkx FHM, Schalekamp MADH, Dooijewaard G, Klaauw MMvd. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man. Thromb Haemostas 1988; 59: 404-11
• 3 Keber D. Mechanism of tissue plasminogen activator release during venous occlusion. Fibrinolysis 1988; 2 (Supp 2) 96-103
• 4 Kruithof EKO, Nicolosa G, Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood 1987; 70: 1645-53
• 5 Hekman CM, Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator. Arch Biochem Biophys 1988; 262: 199-210
• 6 Coleman PL, Patel PD, Cwikel BJ, Rafferty UM, Sznycer R, Gelehrter TC. Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem 1986; 261: 4352-7
• 7 Chandler WL, Schmer G, Stratton JR. Optimum conditions for the stabilization and measurement of tissue plasminogen activator in human plasma. J Lab Clin Med 1989; 113: 362-71
• 8 Chandler WL, Loo SC, Nguyen SV, Schmer G, Stratton JR. Standardization of methods for measuring plasminogen activator inhibitor (PAI-1) activity in human plasma. Clin Chem 1989; 35: 787-93
• 9 Chandler WL, Trimble SL, Loo SC, Mornin D. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma. Blood 1990; 76: 930-7
• 10 Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-9
• 11 Chandler WL, Mornin D, Whitten RO, Angleton P, Farin FM, Fritsche TR, Veith RC, Stratton JR. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. Thromb Res 1990; 58: 1-12
• 12 Gaffney PJ, Curtis AD. A collaborative study to establish the 2nd international standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1987; 58: 1085-7
• 13 Rånby M, Bergsdorf N, Nilsson T, Mellbring G, Winblad B, Bucht G. Age dependence of tissue plasminogen activator concentrations in plasma as studied by an improved enzyme-linked immunosorbent assay. Clin Chem 1986; 32: 2160-5
• 14 Rånby M, Nguyen G, Scarabin PY, Samama M. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Thromb Haemostas 1989; 61: 409-14
• 15 Selkurt EE. Physiology. Little, Brown, Boston: 1976
• 16 Schmidt RF, Thews G. Human Physiology. Springer-Verlag, Berlin: 1983
• 17 van Hinsbergh VWM. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitor by endothelial cells. In: Tissue-Type Plasminogen Activator (t-PA): Physiological and Clinical Aspects.. Kluft C. (ed) CRC Press, Boca Raton, CA: 1988. 2 3-20
• 18 Krause J. Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids. Fibrinolysis 1988; 2: 133-42
• 19 Kruithof EKO. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis 1988; 2 (Suppl 2) 59-70
• 20 Nilsson S, Einarsson S, Ekvarn S, Haggroth L, Mattsson C. Turnover of tissue plasminogen activator in normal and hepatectomized rabbits. Thromb Res 1985; 39: 511-21
• 21 Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24
• 22 Mathews JH. Numerical Methods for Computer Science, Engineering, and Mathematics. Prentice-Hall, Englewood Cliffs, NJ: 1987
• 23 Snedecor GW, Cochran WG. Statistical Methods. 17th ed. Iowa State University Press, Ames, Iowa: 1980
• 24 Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101-6
• 25 Tanswell P, Schlüter M, Krause J. Pharmacokinetics and isolated liver perfusion of carbohydrate modified recombinant tissue-type plasminogen activator. Fibrinolysis 1989; 3: 79-84